Sulphonamides incorporating 1,3,5-triazine structural motifs show antioxidant, acetylcholinesterase, butyrylcholinesterase, and tyrosinase inhibitory profile

References

• Zheng M, Xu C, Ma J, et al. Synthesis and antitumor evaluation of a novel series of triamino triazine derivatives. Bioorg Med Chem 2007;15:1815–27.
   PubMedGoogle Scholar
• Patel RV, Keum YS, Park SW. Medicinal chemistry discoveries among 1,3,5-triazines: recent advances (2000-2013) as antimicrobial, anti-TB, anti-HIV and antimalarials. Mini Rev Med Chem 2014;14:768–89.
   PubMed Web of Science ®Google Scholar
• Liu B, Sun T, Zhou Z, Du L. A systematic review on antitumor agents with 1,3,5-triazines. Med Chem 2015;5:131–48.
   Google Scholar
• Cascioferro S, Parrino B, Spano V, et al. 1,3,5-Triazines: a promising scaffold, for anticancer drugs development. Eur J Med Chem 2017;142:523–49.
   PubMed Web of Science ®Google Scholar
• Garaj V, Puccetti L, Fasolis G, et al. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties. Bioorg Med Chem Lett 2004;14:5427–33.
   PubMed Web of Science ®Google Scholar
• a) Havrankova E, Csollei J, Vullo D, et al. Novel sulfonamide incorporating piperazine, aminoalcohol and 1,3,5-triazine structural motifs with carbonic anhydrase I, II and IX inhibitory action. Bioorg Chem 2018;77:25–37.
   PubMed Web of Science ®Google Scholar
  b) Garaj V, Puccetti L, Fasolis G, et al. Carbonic anhydrase inhibitors: Novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II, and IX. Bioorg Med Chem Lett 2005;15:3102–8.
   PubMed Web of Science ®Google Scholar
  c) Mikus P, Krajciova D, Mikulova M, et al. Novel sulfonamides incorporating 1,3,5-triazine and amino acid structural motifs as inhibitors of the physiological carbonic anhydrase isozymes I, II, and IV and tumor-associated isozyme IX. Bioorg Chem 2018;81:241–52.
   PubMed Web of Science ®Google Scholar
• a) Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nature Rev Drug Discov 2008;7:168–81;
   PubMed Web of Science ®Google Scholar
  b) Alterio V, Di Fiore A, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 2012;112:4421–68;
   PubMed Web of Science ®Google Scholar
  c) Supuran CT. Structure and function of carbonic anhydrases. Biochem J 2016;473:2023–32;
   PubMed Web of Science ®Google Scholar
  d) Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem 2016;31:345–60.
   PubMed Web of Science ®Google Scholar
• a) Supuran CT. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs 2018;27:963–70;
   PubMed Web of Science ®Google Scholar
  b) Nocentini A, Supuran CT. Advances in the structural annotation of human carbonic anhydrases and impact on future drug discovery. Expert Opin Drug Discov 2019;14:1175–97;
   PubMed Web of Science ®Google Scholar
  c) Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov 2017;12:61–88;
   PubMed Web of Science ®Google Scholar
  d) De Simone G, Supuran CT. (In)organic anions as carbonic anhydrase inhibitors. J Inorg Biochem 2012;111:117–29.
   PubMed Web of Science ®Google Scholar
• a) Ceruso M, Vullo D, Scozzafava A, Supuran CT. Inhibition of human carbonic anhydrase isoforms I-XIV with sulfonamides incorporating fluorine and 1,3,5-triazine moieties. Bioorg Med Chem 2013;21:6929–36;
   PubMed Web of Science ®Google Scholar
  b) Carta F, Garaj V, Maresca A, et al. Sulfonamides incorporating 1,3,5-triazine moieties selectively and potently inhibit carbonic anhydrase transmembrane isoforms IX, XII, and XIV over cytosolic isoforms I and II: solution and X-ray crystallographic studies. Bioorg Med Chem 2011;19:3105–19;
   PubMed Web of Science ®Google Scholar
  c) Oztürk Sarikaya SB, Topal F, Sentürk M, et al. In vitro inhibition of α-carbonic anhydrase isozymes by some phenolic compounds. Bioorg Med Chem Lett 2011;21:4259–62.
   PubMed Web of Science ®Google Scholar
• a) Supuran CT. Carbonic Anhydrases and Metabolism. Metabolites 2018;8:25;
   PubMed Web of Science ®Google Scholar
  b) Supuran CT. Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas. Expert Opin Ther Pat 2018;28:709–12;
   PubMed Web of Science ®Google Scholar
  c) Supuran CT. Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases. Expert Opin Ther Pat 2018;28:713–21;
   PubMed Web of Science ®Google Scholar
  d) Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767–77;
   PubMed Web of Science ®Google Scholar
  e) Supuran CT, Alterio V, Di Fiore A, et al. Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: Three for the price of one. Med Res Rev 2018;38:1799–836.
   PubMed Web of Science ®Google Scholar
• a) Lolak N, Akocak S, Bua S, Supuran CT. Design, synthesis and biological evaluation of ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as potent carbonic anhydrase IX inhibitors. Bioorg Chem 2019;82:117–22;
   PubMed Web of Science ®Google Scholar
  b) Lolak N, Akocak S, Bua S, et al. Discovery of new ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as carbonic anhydrase I, II, IX and XII inhibitors. Bioorg Med Chem 2019;27:1588–94.
   PubMed Web of Science ®Google Scholar
• a) Tars K, Vullo D, Kazaks A, et al. Sulfocoumarins (1,2-benzoxathiine 2,2-dioxides): a class of potent and isoform-selective inhibitors of tumor-associated carbonic anhydrases. J Med Chem 2013;56:293–300;
   PubMed Web of Science ®Google Scholar
  b) Köhler K, Hillebrecht A, Schulze Wischeler J, et al. Saccharin inhibits carbonic anhydrases: possible explanation for its unpleasant metallic aftertaste. Angew Chem Int Ed Engl 2007;46:7697–9;
   PubMed Web of Science ®Google Scholar
  c) Nishimori I, Minakuchi T, Morimoto K, et al. Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs. J Med Chem 2006;49:2117–26.
   PubMed Web of Science ®Google Scholar
• a) Bag S, Tulsan R, Sood A, et al. Sulfonamides as multifunctional agents for Alzheimer’s disease. Bioorg Med Chem 2015;25:626–30;
   Web of Science ®Google Scholar
  b) Gocer H, Akincioglu A, Goksu S, et al. Carbonic anhydrase and acetylcholinesterase inhibitory effects of carbamates and sulfamoylcarbamates. J Enzyme Inhib Med Chem 2014;30:316–20;
   PubMed Web of Science ®Google Scholar
  c) Scozzafava A, Kalin P, Supuran CT, et al. The impact of hydroquinone on acetylcholine esterase and certain human carbonic anhydrase isoenzymes (hCA I, II, IX, and XII). J Enzyme Inhib Med Chem 2015;30:941–6;
   PubMed Web of Science ®Google Scholar
  d) Gulcin I, Scozzafava A, Supuran CT, et al. The effect of caffeic acid phenethyl ester (CAPE) on metabolic enzymes including acetylcholinesterase, butyrylcholinesterase, glutathione S-transferase, lactoperoxidase, and carbonic anhydrase isoenzymes I, II, IX, and XII. J Enzyme Inhib Med Chem 2016;31:1095–101.
   PubMed Web of Science ®Google Scholar
• a) Rishton GM, Retz DM, Tempest PA, et al. Fencyhylamine sulfonamide inhibitors of amyloid beta peptide production by the gamma-secretase proteolytic pathway: potential small-molecule therapeutic agents for the treatment of Alzheimer’s disease. J Med Chem 2000;43:2297–9;
   PubMed Web of Science ®Google Scholar
  b) Gocer H, Topal F, Topal M, et al. Acetylcholinesterase and carbonic anhydrase isoenzymes I and II inhibition profiles of taxifolin. J Enzyme Inhib Med Chem 2016;31:441–7;
   PubMed Web of Science ®Google Scholar
  c) Ozgeris B, Goksu S, Kose LP, et al. Acetylcholinesterase and carbonic anhydrase inhibitory properties of novel urea and sulfamide derivatives incorporating dopaminergic 2-aminotetralin scaffolds. Bioorg Med Chem 2016;24:2318–29;
   PubMed Web of Science ®Google Scholar
  d) Akincioglu A, Akincioglu H, Durdagi S, et al. Discovery of potentcarbonic anhydrase and acetylcholine esterase inhibitors: Novel sulfamoyl carbamates and sulfamides derived from acetophenones. Bioorg Med Chem 2015;23:3592–602.
   PubMed Web of Science ®Google Scholar
• a) Wang J, Gu BJ, Masters CL, Wang YJ. A systemic view of Alzheimer disease-insights from amyloid-β metabolism beyond the brain. Nat Rev Neurol 2017;13:612–23;
   PubMed Web of Science ®Google Scholar
  b) Yilmaz S, Akbaba Y, Ozgeris B, et al. Synthesis and inhibitory properties of some carbamates on carbonic anhydrase and acetylcholine esterase. J Enzyme Inhib Med Chem 2016;31:1484–91;
   PubMed Web of Science ®Google Scholar
  c) Ozgun DO, Yamali C, Gul HI, et al. Inhibitory effects of isatin Mannich bases on carbonic anhydrases, acetylcholinesterase, and butyrylcholinesterase. J Enzyme Inhib Med Chem 2016;31:1498–501.
   PubMed Web of Science ®Google Scholar
• a) Alzheimer’s Disease International. World Alzheimer Report 2019: attitudes to dementia. London: Alzheimer’s Disease International. Available from: https://www.alz.co.uk/research/WorldAlzheimerReport2019.pdf [last accessed 19 Dec 2019];
   Google Scholar
  b) Swerdlow RH. Pathogenesis of Alzheimer's disease. Clin Interv Aging 2007;2:347–59.
   PubMed Web of Science ®Google Scholar
• Dong S, Duan Y, Hu Y, Zhao Z. Advances in the pathogenesis of Alzheimer’s disease: a re-evaluation of amyloid cascade hypothesis. Transl Neurodegener 2012;1:1–18.
   PubMedGoogle Scholar
• Greig NH, Lahiri DK, Sambamurti K. Butyrylcholinesterase: an important new target in Alzheimer’s disease therapys. Int Psychogeriatr 2002;14:77–91.
   PubMed Web of Science ®Google Scholar
• Klatte ET, Scharre DW, Nagaraja HN, et al. Combination therapy of donepezil and vitamin E in Alzheimer disease. Alzheimer Dis Assoc Disord 2003;17:113–6.
   PubMed Web of Science ®Google Scholar
• Cai P, Fang SQ, Yang HL, et al. Donepezil-butylated hydroxytoluene (BHT) hybrids as Anti-Alzheimer’s disease agents with cholinergic, antioxidant, and neuroprotective properties. Eur J Med Chem 2018;157:161–76.
   PubMed Web of Science ®Google Scholar
• Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer’s disease. Arch Pharm Res 2013;36:375–99.
   PubMed Web of Science ®Google Scholar
• L.G. de Souza LG, Renno MN, Figueroa-Villar JD. Coumarins as cholinesterase inhibitors: a review. Chem Biol Interact 2016;254:11–23.
   PubMed Web of Science ®Google Scholar
• Blois MS. Antioxidant determinations by the use of a stable free radical. Nature 1958;181:1199–200.
   Web of Science ®Google Scholar
• Akocak S, Boga M, Lolak N, et al. Design, synthesis and biological evaluation of 1,3-diaryltriazene-substituted sulfonamides as antioxidant, acetylcholinesterase, and butyrylcholinesterase inhibitors. J Turk Chem Soc Sect A: Chem 2019;6:63–70.
   Google Scholar
• Gulcin I. Antioxidant activity of caffeic acid (3,4-dihydroxycinnamic acid). Toxicology 2006;217:213–20.
   PubMed Web of Science ®Google Scholar
• Gulcin I. Antioxidant and antiradical activities of L-carnitine. Life Sciences 2006;78:803–11.
   PubMed Web of Science ®Google Scholar
• Ak T, Gulcin I. Antioxidant and radical scavenging properties of curcumin. Chem Biol Interact 2008;174:27–37.
   PubMed Web of Science ®Google Scholar
• Gulcin I. Comparison of in vitro antioxidant and antiradical activities of L-tyrosine and L-Dopa. Amino Acids 2006;32:431–8.
   PubMed Web of Science ®Google Scholar
• Pellegrini RRN, Proteggente A, Pannala A, et al. Antioxidant activity applying and improved ABTS radical cation decolorization assay. Free Rad Bio Med 1999;26:1231–7.
   PubMed Web of Science ®Google Scholar
• Akocak S, Lolak N, Tuneg M, Boga M. Antioxidant, acetylcholinesterase and butyrylcholinesterase inhibition profiles of histamine Schiff bases. J Turk Chem Soc Sect A: Chem 2019;6:157–64.
   Google Scholar
• Dinis TCP, Madeira VMC, Almeida LM. Action of phenolic derivatives (acetoaminophen, salycilate and 5-aminosalycilate) as inhibitors of membrane lipid preoxidation and as preoxyl radical scavengers. Arc Biochem Biophy 1994;315:161–9.
   PubMed Web of Science ®Google Scholar
• Gulcin I. Antioxidant activity of L-adrenaline: a structure-activity insight. Chem Biol Interact 2009;179:71–80.
   PubMed Web of Science ®Google Scholar
• Gulcin I. Antioxidant properties of resveratrol: a structure-activity insight. Innovative Food Sci Emerg Tech 2010;11:210–8.
   Web of Science ®Google Scholar
• Gulcin I, Bursal E, Sehitoglu MH, et al. Polyphenol contents and antioxidant activity of lyophilized aqueous extract of propolis from Erzurum, Turkey. Food Chem Toxicol 2010;48:2227–38.
   PubMed Web of Science ®Google Scholar
• Ellman GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95.
   PubMed Web of Science ®Google Scholar
• Hearing VJ, Jiménez M. Mammalian tyrosinase - the critical regulatory control point in melanocyte pigmentation. Int J Biochem 1987;19:1141–7.
   PubMedGoogle Scholar
• Zolghadri S, Bahrami A, Khan MTH, et al. comprehensive review on tyrosinase inhibitors. J Enzyme Inhib Med Chem 2019;34:279–309.
   PubMed Web of Science ®Google Scholar
• Sahu RK, Roy A, Dwivedi J, Jha AK. Promotion and computation of inhibitory effect on tyrosinase activity of herbal cream by incorporating indigenous medicinal plants. Pak J Biol Sci 2014;17:146–50.
   PubMedGoogle Scholar
• Sohretoglu D, Sari S, Barut B, Ozel A. Tyrosinase inhibition by some flavonoids: inhibitory activity, mechanism by in vitro and in silico studies. Bioorg. Chem 2018;81:168–74.
   PubMed Web of Science ®Google Scholar
• Halaouli S, Asther M, Kruus K, et al. Characterization of new tyrosinase from Pycnoporus species with high potential for food technological applications. J Appl Microbiol 2005;98:332–43.
   PubMed Web of Science ®Google Scholar